Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD)
Sponsor: Deepa Jagadeesh
Terminated
Slow accrual
A PHASE2 clinical study on Post-transplant Lymphoproliferative Disorder, this trial is terminated or withdrawn. The trial is conducted by Deepa Jagadeesh and has accumulated 12 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — May 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Deepa Jagadeesh
For direct contact, visit the study record on ClinicalTrials.gov .